Applied Filters
Cancer centre sues BMS and Ono over alleged patent exploitation
Boston-based Dana-Farber Cancer Institute is seeking a share of the $1.6 billion in licensing revenue that BMS and Ono Pharmaceutical Co have allegedly received from six immunotherapy patents.
English High Court refuses to grant Pfizer Arrow declaration
Pfizer’s attempt to secure an Arrow declaration in relation to its proposed launch of a cancer drug in Europe was shot down yesterday, June 20, by the English High Court.
Pfizer to acquire Array BioPharma for $11.4bn
US biopharmaceutical company Pfizer has entered agreed to acquire Array BioPharma, a biotechnology company which develops small molecule drugs for the treatment of cancer.
GSK unites with CRISPR pioneer Doudna
British-based pharmaceutical company GSK has entered into a five-year collaboration with the University of California to explore how gene mutations cause disease and accelerate drug discovery.
BASF appeals to Federal Circuit in agritech dispute
BASF Plant Science, the plant biotech-focused subsidiary of BASF, has asked the US Court of Appeals for the Federal Circuit to overturn a finding that certain claims of a transgenic plant technology patent were invalid.
Russian scientist pledges to make more CRISPR-edited babies
A Russian scientist is planning to create CRISPR-edited babies, despite the widespread condemnation levelled at the first scientist who created ‘edited’ twins.
Avocado company drops plant patent suit against rival
Dominican Republic-based Agroindustrial Ocoeña has asked a US court to dismiss its plant patent claim against a competitor run by the patent inventor’s brother.
Merck strengthens immunotherapy expertise with $773m buy
US-based Merck & Co has announced plans to buy Tilos Therapeutics, its latest acquisition in the immunotherapy space.
USITC issues judgment in cholesterol testing strips dispute
The US International Trade Commission has issued a judgment after a surgical appliances company, Polymer Technology Systems (PTS), filed a complaint against a China-based competitor.
Eli Lilly secures exclusive rights to chronic pain treatment
American pharmaceutical company Eli Lilly has secured an exclusive licence for a non-opioid, non-addictive chronic pain treatment from Boston-based biotech company Centrexion Therapeutics.
